Compare VHC & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHC | IVVD |
|---|---|---|
| Founded | 2005 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.7M | 692.7M |
| IPO Year | 1999 | 2021 |
| Metric | VHC | IVVD |
|---|---|---|
| Price | $18.67 | $2.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 15.5K | ★ 12.0M |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $106,000.00 | ★ $50,039,000.00 |
| Revenue This Year | N/A | $103.88 |
| Revenue Next Year | N/A | $171.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2020.00 | 332.71 |
| 52 Week Low | $3.68 | $0.35 |
| 52 Week High | $29.00 | $3.07 |
| Indicator | VHC | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 39.68 | 53.98 |
| Support Level | $18.13 | $2.09 |
| Resistance Level | $23.70 | $2.60 |
| Average True Range (ATR) | 1.89 | 0.22 |
| MACD | -0.63 | -0.04 |
| Stochastic Oscillator | 5.52 | 17.86 |
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.